Carbonnaux M, et al. - In a large cohort of patients with metastatic soft tissue sarcomas (STS), researchers assessed the incidence, presenting features of, and management strategies for long-term survivors. From a group of patients with metastatic STS, they compared patients alive 5 years following the diagnosis of metastases vs the others. A median survival of 146 months (12 years) was reported in 39 (9%) out of 436 patients who were still alive 5 years after diagnosis of metastases. The characteristics of this “long-term survivors” group were a predominance of female and younger patients, better performance status, more synovial sarcoma or endometrial stromal sarcoma, more patients with simple genomic sarcomas, lower tumor grade, smaller tumor, and longer disease-free interval. Factors that displayed significant relation to the long-term survivors were age below 55 at metastatic stage and grade 1 tumor. Usually, these subjects received aggressive therapeutic management (intensified or polychemotherapy, repeated local treatment of metastases), which resulted in 62% of complete response in first-line setting.